| Name | Pemirolast potassium |
| Description | Pemirolast Potassium is the potassium salt form of pemirolast, a pyrimidinone derivative with antiallergic property. Pemirolast potassium (TWT-8152) exerts its action by blocking the antigen-mediated calcium ion influx into mast cells. |
| In vitro | Pemirolast potassium inhibits the release of peptides from sensory nerves (substance P, neurokinin (NK) A, and CGRP) and inhibits the release of chemical mediators from tissue mast cells, which are commonly used in the treatment of allergic reactions. |
| In vivo | Pemirolast potassium inhibits the release of peptides from sensory nerves (substance P, neurokinin (NK) A, and CGRP) and inhibits the release of chemical mediators from tissue mast cells, which are commonly used in the treatment of allergic reactions. |
| Storage | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | H2O : 10 mM, Sonication is recommended. DMSO : Insoluble
|
| Keywords | TWT8152 | TWT 8152 | Pemirolast potassium | Pemirolast | Inhibitor | inhibit | HistamineReceptor | Histamine Receptor | H1 receptor | BMY-26517 | BMY26517 |
| Inhibitors Related | Undecane | Betahistine mesylate | Histamine dihydrochloride | Meclizine dihydrochloride | Lidocaine | Famotidine | Sodium butanoate | Nizatidine | Alginic acid | Mianserin hydrochloride | Trazodone hydrochloride | Doxepin hydrochloride |
| Related Compound Libraries | Failed Clinical Trials Compound Library | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Drug Repurposing Compound Library | Inhibitor Library | FDA-Approved Drug Library | Anti-Cancer Approved Drug Library | Immunology/Inflammation Compound Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | GPCR Compound Library | Anti-Cancer Drug Library |